Employees Retirement System of Texas lowered its position in Emergent Biosolutions, Inc. (NYSE:EBS) by 9.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 116,000 shares of the biopharmaceutical company’s stock after selling 12,000 shares during the quarter. Employees Retirement System of Texas owned 0.28% of Emergent Biosolutions worth $3,934,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Stifel Financial Corp lifted its position in shares of Emergent Biosolutions by 3.9% in the 2nd quarter. Stifel Financial Corp now owns 13,572 shares of the biopharmaceutical company’s stock worth $461,000 after acquiring an additional 513 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Emergent Biosolutions by 7.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,205,712 shares of the biopharmaceutical company’s stock worth $74,795,000 after acquiring an additional 152,029 shares during the period. Renaissance Technologies LLC lifted its position in shares of Emergent Biosolutions by 16.7% in the 2nd quarter. Renaissance Technologies LLC now owns 820,411 shares of the biopharmaceutical company’s stock worth $27,820,000 after acquiring an additional 117,700 shares during the period. Parametric Portfolio Associates LLC lifted its position in shares of Emergent Biosolutions by 3.0% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 141,608 shares of the biopharmaceutical company’s stock worth $4,802,000 after acquiring an additional 4,080 shares during the period. Finally, Nordea Investment Management AB lifted its position in shares of Emergent Biosolutions by 27.5% in the 2nd quarter. Nordea Investment Management AB now owns 62,082 shares of the biopharmaceutical company’s stock worth $2,105,000 after acquiring an additional 13,379 shares during the period. Institutional investors own 85.35% of the company’s stock.

Shares of Emergent Biosolutions, Inc. (NYSE EBS) opened at 40.50 on Friday. Emergent Biosolutions, Inc. has a 12 month low of $24.47 and a 12 month high of $41.46. The firm has a 50 day moving average price of $37.85 and a 200-day moving average price of $33.49. The company has a market cap of $1.67 billion, a P/E ratio of 25.80 and a beta of 1.26.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.26 by ($0.13). The company had revenue of $100.77 million during the quarter, compared to the consensus estimate of $111.57 million. Emergent Biosolutions had a net margin of 13.42% and a return on equity of 14.50%. The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.05) earnings per share. Analysts anticipate that Emergent Biosolutions, Inc. will post $1.54 earnings per share for the current fiscal year.

In related news, CEO Daniel Abdun-Nabi sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $37.21, for a total value of $558,150.00. Following the completion of the sale, the chief executive officer now directly owns 219,134 shares in the company, valued at $8,153,976.14. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Adam Havey sold 7,885 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The shares were sold at an average price of $37.06, for a total value of $292,218.10. Following the completion of the sale, the executive vice president now owns 33,931 shares of the company’s stock, valued at $1,257,482.86. The disclosure for this sale can be found here. Over the last quarter, insiders sold 230,227 shares of company stock valued at $8,793,970. 16.50% of the stock is currently owned by corporate insiders.

A number of analysts have commented on the company. Zacks Investment Research downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. BidaskClub upgraded Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. Finally, Wells Fargo & Company reiterated an “outperform” rating and issued a $43.00 price objective (up previously from $41.00) on shares of Emergent Biosolutions in a research report on Saturday, September 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $45.00.

ILLEGAL ACTIVITY NOTICE: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/08/employees-retirement-system-of-texas-trims-holdings-in-emergent-biosolutions-inc-ebs.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Stock Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related stocks with our FREE daily email newsletter.